-Parse Biosciences, a leading provider of cost-effective and scalable solutions for single-cell sequencing, today announced an agreement with the Taiwanese company Prisma Biotech to expand the reach of Parse in Taiwan and throughout the Asia-Pacific region.

"Biotech, pharmaceutical and academic researchers across Asia are boosting demand in the region for the Evercode solutions for single-cell sequencing of Parse as they discover their scalability and simplicity," said Dr. Alex Rosenberg, CEO and co-founder of Parse Biosciences. "We are pleased that through our partnership with Prisma, we can give them the opportunity to easily take advantage of Parse's single-cell sequencing technology."

The company's agreement with Prisma Biotech will give a larger number of Asian researchers full access to Parse's single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode BCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Select, CRISPR Detect and the data analysis solution of Parse Biosciences, Trailmaker. The agreement is a continuation of the ongoing market penetration of Parse in Asia, including South Korea, Singapore and India, as well as in key international markets such as North America, Europe, Australia, Israel and New Zealand.

"Products for single cell sequencing are in high demand, and Parse's Evercode technology is extremely convincing due to its scalability and ease of use," said Kevin Tseng, CEO of Prisma Biotech. "Our partnership with Parse will make single cell sequencing available to a wide range of researchers in Taiwan and throughout the Asia-Pacific region, and we look forward to supporting scientific discoveries that enable these tools."